NTHI news

NeOnc Technologies announced it will present data on its NEO100 and NEO212 clinical programs at the Society for Neuro-Oncology's 2026 Annual Meeting, highlighting progress in CNS cancer therapies. The data event adds visibility to the clinical development pipeline and therapeutic potential of the co…

The Company announced early clinical improvements reported by treating physicians in a three-year-old boy at the Department of Health -- Abu Dhabi, a critical development for the pipeline as IND authorization expands.

NeOnc will meet with FDA in November to review its Phase 2 design for the gastric cancer drug NEO212. The company reported encouraging clinical data from the previous Phase 1 trials.

CEO Amir Heshmatpour bought 35,000 shares for approx $115,400 on Sept 15, 2026. Execs have invested $629,000 since releasing positive phase 2a trial results.

NeOnc Technologies received detailed FDA feedback regarding the Chemistry, Manufacturing and Controls for its NEO212 candidate, including actionable steps for a tablet formulation transition. The constructive guidance allows the company to proceed with a staged stability program, supporting the adva…

NeOnc Technologies received UAE IND approval for its lead candidate NEO100 across multiple dosing protocols. This authorization complements recent UAE clearance for NEO212 and precedes the imminent Phase 2a data readout in July.